In retrospective analyses of lenvatinib use in 2L therapy, factors such as AFP < 400 ng/mL, no extrahepatic spread, Child–Pugh A, tumor number < 3, ORR under first-line treatment, and a PFS ≥ 6 months were positive prognostic factors for improved survival [41,42]. Here, AFP is linked to neoplasm.